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Japanese encephalitis virus (JEV) remains one of the major causative agents of pediatric encephalitis.
Interaction of dendritic cells (DCs) with innate lymphocytes (NK and NKT) represents a crucial event
during anti-viral innate immune response. In the current study, we have tried to understand the
interaction between JEV, human monocyte derived DCs (MDDCs), and CD56þ cells (NKþNKT) in-vitro.
We have used two JEV strains (i) JE057434 (neurovirulent, wild-type) and (ii) SA14-14-2 (non-
neurovirulent, live-attenuated vaccine) to investigate the effect of viral virulence on the functional
status of primary human MDDCs. Our preliminary results indicate that replicating JEV induces MDDCs
maturation via PI3K and p38 pathways. We also show that the presence of IL2-activated CD56þ cells
impart both immunomodulatory and anti-viral effects on DCs infected with JEV. Mechanistic studies
illustrate that, IL2-activated CD56þ lymphocytes mediated immunomodulation occurs through direct
cell-to-cell contact and TNFa, while the anti-viral effect is dependent on direct cell-to-cell contact.
& 2012 Elsevier Inc. All rights reserved.Introduction
Dendritic cells (DCs) are professional antigen presenting cells
and act as sentinels at the periphery. On viral infection, these cells
undergo maturation and activate a cascade of both innate and
adaptive anti-viral immune response. DCs can act as carriers of
viral load (Trojan horse) and are susceptible to virus-mediated
modulation (Rinaldo and Piazza, 2004). Apart from DCs, natural
killer (NK) and natural killer T (NKT) cells are CD56þ innate
lymphocytes that bridge the gap between the innate and adaptive
system. These cells contribute to DCs maturation through immu-
nomodulation, and provide primary anti-viral defense (Biron and
Brossay, 2001; Mu¨nz et al., 2005). NK-DC interactions are bi-
directional and can occur at various sites including the site of
inﬂammation (Cooper et al., 2004; Moretta, 2005). Therefore,
interaction of DCs with innate lymphocytes represents a major
control mechanism in limiting the virus infection at the periphery
before adaptive response sets-in.
Japanese encephalitis virus (JEV) is a mosquito-borne, ssRNA
(11 kb, monopartite, linear) virus belonging to family Flaviviridae
and genus Flavivirus. JEV remains as one of the major causative
agents of pediatric encephalitis, and is mainly prevalent in South
East Asian countries and the Paciﬁc’s (Erlanger et al., 2009).ll rights reserved.
).In humans, clinical presentation of JEV infection ranges from mild
febrile illness to severe meningoencephalitis (Solomon, 2003).
However, in JEV endemic region most of the JEV infections manifest
in mild febrile, sub-clinical disease (http://www.cdc.gov/ncidod/
dvbid/jencephalitis/facts.htm) and leading to protective adaptive
response (Kumar et al., 2004).
During viral infection, both virus virulence factor and host
factors appear to inﬂuence the pathogenesis. In vivo and in vitro
studies have shown that JEV replicates in macrophages, and
human mononuclear leukocytes (Aleyas et al., 2009; Mathur
et al., 1988; Kedarnath et al., 1986). Recently, two groups have
independently shown that wild-type JEV impairs the functional
status of mouse DCs and thus leading to poor T cell response
(Aleyas et al., 2009; Cao et al., 2011). In several ﬂavivirus
infections such as West Nile (WNV), Hepatitis C virus and dengue
virus (DENV), NK and NKT cells are known to reduce virus load
(Ye et al., 2009; Zhang et al., 2010) and curtail viral spread
(Shresta et al., 2004). In humans, an increase in early NK and
NKT activation is associated with mild dengue disease (Azeredo
et al., 2006). However, the role of NK and NKT cells in modulating
DCs maturation and anti-viral effect during JEV infection remains
unresolved.
The aim of our study was to evaluate (a) the interaction
between JEV, human monocyte derived DCs (MDDCs) and
CD56þ cells (NKþNKT) in vitro; and (b) differential ability of
different JEV strains to induce and/or respond to this interac-
tion. We used two JEV strains—JE057434 (neurovirulent, primary
Table 1
Nucleotide and amino-acid differences between wild-type (JE057434) and vaccine
(SA14-14-2) JEV strain genome coding region.
Position Nucleotide Amino acid
Ca T292C L66S
A441G T116A
prM G648A,C649T A58M
H. Sooryanarain et al. / Virology 432 (2012) 250–260 251clinical isolate, as wild-type strain) and SA14-14-2 (non-neuro-
virulent, live-attenuated, commercial, JEV vaccine strain) to
understand the effect of viral virulence in modulating DC-
CD56þ cell interaction. Our results indicate the replication of
JEV in immature-MDDCs and subsequent activation and matura-
tion of these cells. We also conﬁrm the contribution of CD56þ-NK
and -NKT cells in increased DCs maturation and an overall
decrease in JE virus load.C841T T122M
E C1296T L107F
G1389A E138K
A1458G T161A
A1503G I176V
A1506G T177A
A1708G E244G
G1769T Q264H
A1813T K279M
C1921T A315V
G2064A A363T
G2170A R398K
A2293G K439R
G2317A G447D
NS1 T3165A S230T
G3181A G235D
T3216A L247I
G3351A G292S
C3489G,C3491T L338V
G3493T R339M
G3528C D351H
T3539A N354K
C3652T A392V
NS2A G3972A, T3974C A84T
A4085C Q121H
NS2B G4403T E63D
A4408G D65G
G4475C L87F
NS3 A4782G M59V
C4921G,T4922C A105G
A5114C E169D
C5172A L189M
C5311T A235V
G5656A G350E
NS4A NIL NL
NS4B A7227G I106V
C7243T S111F
T7263C V118A
NS5 T7683C S3P
C7768G A31G
C7809A R45S
G7821A V49I
G8261T M195I
A8490G I272V
C8832T H386Y
G9593T Q639H
T9688C V671A
G9954C A760P
C9978G L768V
A10081T K802I
G10371A V899I
a C—Capsid; prM—pre-membrane; E—envelope; NS—non-structural.Results
Genetic and phenotypic characterization of JE057434 and SA14-14-2
JE057434 (wild-type) was isolated from human clinical sample
obtained from Gorakhpur region of India in 2005. Comparison of
both nucleotide and protein sequences of JE057434 (GenBank ID:
EF623988.1) and SA14-14-2 (GenBank ID: AF315119.1) was per-
formed using MEGA5 software. Both strains belonged to genotype III
and exhibited a 97.48% genome similarity. A total of 276 nucleotides
and 53 amino acid differences were observed between both the
viruses. The major nucleotide and amino acid changes within the
coding regions of both virus genomes are shown in Table 1. Prime
changes, between JE057434 and SA14-14-2, at E138K, I176V,
Q264H, K279M, A315V, and K439R in E protein, E63D in NS2B,
A105G in NS3, and I106V in NS4B resembled the mutations
observed between SA14 (GenBank ID: M55506.1) and SA14-14-2 E
and NS regions. JE057434 was neurovirulent in mice.
Anti-ﬂavivirus immune status
The donor’s sera were screened for neutralizing antibody (N-Ab)
against DENV, WNV, and JEV. Ninety percent of the donors were
seropositive for either of the ﬂavivirus tested, predominantly to
WNV or DENV. The geo-mean7SEM of N-Ab titer for DENV¼
35.45726.93 (range: 7–896); WNV¼84.87711.76 (range: 28–
336); and JEV¼17.0271.08 (range: 7–56). Moreover, in humans,
anamnestic anti-ﬂavivirus immune response is also known to con-
tribute to protection from severe JE disease, rather than causing
antibody dependent enhancement as seen in secondary dengue
infections (Libraty et al., 2002; Solomon, 2004).
Throughout our study, in vitro JEV infection of immature-
MDDCs (im-MDDCs) or mature-MDDCs (m-MDDCs) was carried
out in complete absence of external neutralizing antibody or
donor’s autologous sera. Therefore, we assume that there is no
possibility of antibody dependent enhancement inﬂuencing the
growth kinetics or other response induced by the JEV strains
during these experiments.
JEV replicates in im-MDDCs but not in m-MDDCs
DCs are known to support ﬂavivirus replication. Both, wild-type
and vaccine JEV strains replicated efﬁciently in im-MDDCs; while,
m-MDDCs failed to support replication of JEV strains (Fig. 1A). At
48 h post-infection (hpi), both JEV strains reached a titer of 6 log10
in im-MDDCs, while it remained 1 log10 in m-MDDCs cultures.
Growth kinetics experiment on im-MDDCs showed that both wild-
type and vaccine JEV strains did not vary in their replication
potential. Both JEV strain attained titers with peak at 48 hpi (approx
6 log10) and were maintained until 96 hpi, by 192 hpi the viral load
(approx 3 log10) decreased to basal levels (Fig. 1B).
Flaviviruses use receptor-mediated endocytic pathway to gain
entry into the host cell (Smit et al., 2011; Chu and Ng, 2004) and
the endocytic ability of the DCs diminishes on their maturation
(Guermonprez et al., 2002). Therefore, we speculated that the
difference in im- and m-MDDCs to support JEV might be based onvariation in phagocytic potential or other markers. As a preliminary
experiment, blockage of endocytic ability of im-MDDCs using non-
speciﬁc inhibitors such as Phenylarsine oxide (PAO) or Nocodazole
and Cytochalasin B resulted in reduced FITC-Dextran uptake and
rendered im-MDDCs less susceptible to JEV growth (Fig. S1).
Productive JEV infection brings about activation of im-MDDCs
On pathogen exposure DCs are activated, and efﬁciently
modulate adaptive response through expression of surface
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Fig. 1. im-MDDCs, but not m-MDDCs, support productive JEV replication.
(A) Infectious virus levels, at 48 hpi, in cell-culture supernatant of im-MDDCs
and m-MDDCs infected with wild-type (WT; open bars), or vaccine (Vac; ﬁlled
bars) JEV. (B) Growth kinetics of WT and Vac JEV in im-MDDCs culture. Data
represents mean7SD obtained from three independent experiments.
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in im-MDDCs, both JEV strains were able to up-regulate several
co-stimulatory markers (CD 83, 86, 80, and 40, HLA-A/B/C,
HLA-DR, and ICAM-1) (Fig. 2A). Wild-type JEV strain infection of
im-MDDCs also led to modulation in phagocytic index of the cells
(Fig. 2B). However, JEV infection failed to up-regulate CD86 levels
on m-MDDCs (Fig. S2). We had observed from our earlier experi-
ments, with human macrophages, that most of the immunomo-
dulatory effects of JEV were dependent on virus replication (un-
published data). Thus, we used beta-propiolactone inactivated JEV
to determine whether the JEV replication is needed to up-regulate
co-stimulatory markers on im-MDDCs. The inactivated JEV failed
to induce CD86, CD83 and HLA-DR on im-MDDCs (Fig. 2C). Taken
together, these data indicate both wild-type and vaccine JEV
strains were similar in their ability to induce im-MDDCs matura-
tion and it is dependent on virus replication.
Apart from the co-stimulatory markers, at 48 hpi, JEV infection
also resulted in up-regulation of several cytokines and chemo-
kines levels, as compared with un-infected im-MDDCs culture
supernatant (Fig. 3). The prominent cytokines and chemokines
induced by both JEV strains were type-I IFN, interleukin (IL)-6,
CCL2, CXCL10, and CCL5 (Fig. 3). However, they varied in their
ability to induce tumor necrosis factor (TNF)-a and IL8. Wild-type
JEV strain induced a signiﬁcantly higher TNFa (p¼0.017) and IL8
(p¼0.027) levels as compared with un-infected cultures, while
vaccine JEV failed to do so. JEV infection also resulted in insignif-
icant IL10 release (Fig. 3) and IL12p70 levels remained
undetectable (data not shown); while, inactivated JEV failed to
induce type-I IFN from im-MDDCs (data not shown).PI3K and p38 pathways inﬂuences DC activation during JEV infection
We further characterized the pathway that was involved in DCs
maturation during JEV infection. In accordance with earlier studies
(Aleyas et al., 2009; Chang et al., 2006), blocking of phosphatidyli-
nositol-3-kinase (PI3K) and p38 using speciﬁc inhibitors (LY294002
and SB203580, respectively) resulted in reduced type-I IFN, TFNa,
IL8 (Fig. 4A), and CD86 (Fig. 4B) levels during JEV infection. While,
IL6 level was dependent on PI3K pathway rather than p38 pathway
(Fig. 4A) during JEV infection of im-MDDCs. Interestingly the virus
levels in all the tested conditions remained unaltered (Fig. 4C).
IL2-activated CD56þ cells impart immunomodulation via cell-to-cell
contact and TNFa
During in vivo condition, apart from virus-DC interaction, CD56þ
lymphocytes (NK/ NKT) also determine the course of immune
response. Among the different co-stimulatory molecules determined
CD86 showed highest MFI (mean ﬂuorescence intensity) increase
post-JEV-infection (Fig. 2A) thus in all further experiments levels of
CD86 were used as MDDCs maturation maker.
Presence of IL2-activated CD56þ cells, resulted in DC maturation
as evident from increased CD86 (Fig. 5A), TNFa, IL6, IL1b, and CXCL9
levels (Fig. 5B). However, in the same experiments type-I IFN levels
decreased (Fig. 5B). Conversely, resting CD56þ cells were unable to
modulate CD86 levels andmost of the cytokine or chemokine tested,
with an exception of IL6. Co-culturing of resting CD56þ cells led to
an increased IL6 levels in un-infected and vaccine-JEV infected im-
MDDCs cultures (p¼0.027) (Fig. 5B). Both IL12p70 and IFNg levels
remained undetectable in JEV-infected im-MDDCs cultures, even
during the co-culture experiments (data not shown).
We then determined whether CD56þ-cells-mediated DC
maturation was dependent on cell-to-cell contact—or cytokines
(TNFa). Our results showed IL2-activated CD56þ cells induced
im-MDDCs maturation partially through direct cell-to-cell contact
and TNFa, as separation of the cells by a permeable membrane
(transwell) and presence of neutralizing antibody against TNFa
abrogated DC maturation (Fig. 6A and B).
CD56þ cells mediated anti-viral effect dependent on cell-to-cell
contact and E:T ratio
IL2 treatment is known to augment NK cell killing ability (Grimm
et al., 1982) and cytolytic ability of NK is known to correlate with its
degranulation (i.e., CD107a) levels (Alter et al., 2004). As expected,
the IL2-activated CD56þ cells showed higher degranulation capacity
resulting in increased DC killing (Fig. 7A and B) and greater ability to
reduce JE viral load (Fig. 5C) than resting CD56þ cells. The IL2-
activated CD56þ cells mediated JE virus level reduction through
direct cell-to-cell contact (wild-type JEV¼5.170.25 log10, vaccine
JEV¼3.570.57 log10), as separation of the virus-infected cells and
IL2-activated CD56þ cells by transwell did not result in viral load
reduction (Fig. 8A). In addition, it was independent of TNFa, as
presence of neutralizing antibody against TNFa during co-culture
experiments did not result in increase in JEV titers (wild-type
JEV¼570.1 log10, vaccine JEV¼3.870.28 log10).
The decrease in viral load was more evident in vaccine-JEV
infected im-MDDCs cultures as compared with wild-type JEV strain.
There was approximately 2 log10 reduction in vaccine JE virus level
while only 1 log10 reduction in wild-type JE virus level by IL2-
activated CD56þ cells. The virus level reduction was also dependent
on CD56þ cell number in culture. At higher E:T ratio (5:1), in IL2-
activated CD56þ cells/DC co-cultures, there was increased DC lysis
(Fig. 7B), and wild-type virus level reduction was more predomi-
nant. While, resting CD56þ cells were able to exert a minimal anti-
viral effect even at higher E:T ratio (5:1) (Fig. 8B).
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Fig. 2. Replicating JEV induces DCs maturation. (A) and (C) Histogram overlay representing various co-stimulatory molecule levels on un-infected control (broken line),
wild-type JEV-infected (thick line), vaccine JEV-infected (thin line), and (C) inactivated-JEV infected (black-ﬁlled line) im-MDDCs cultures. Data shown are representative
of three independent experiments. Gray-ﬁlled line represents isotype-matched control. (B) Phagocytic index levels in JEV infected im-MDDCs. CC—un-infected im-MDDCs,
LPS—LPS-treated im-MDDCs (positive control), WT—wild-type JEV-infected im-MDDCs, and Vac—vaccine JEV-infected im-MDDCs. Data represents mean7SD of four
independent experiments. Statistical analysis was done using paired student t-test. *, pr0.05 and **, pr0.01 as compared with un-infected (CC) im-MDDCs; a, pr0.05 on
comparison between wild-type (WT) and vaccine (Vac) JEV-infected im-MDDCs cultures.
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Interplay between the pathogen, DCs and innate lymphocytes
plays a crucial role during initial stages of infection. In the current
study, we have tried to understand the interaction between
human MDDCs, and NKþNKT (CD56þ cells) during wild-type/
vaccine JEV infection in vitro. Our results showed productive JEVreplication results in im-MDDCs activation via PI3K and p38
pathways, and presence of IL2-activated CD56þ cells imparts
both immunomodulatory and anti-viral effect.
Cells of myeloid lineage are known to support JEV (Aleyas
et al., 2009), and viral replication potential forms a major
virulence factor (Hase et al., 1993). We observed that human
im-MDDCs supported a productive JEV replication and a
Fig. 3. Cytokine and chemokine levels. Cytokine and chemokine levels in un-infected (CC), wild-type JEV (WT), or vaccine JEV (Vac) infected im-MDDCs culture
supernatant (n¼7 donors). Box-plots represent minimum, ﬁrst quartile, median, third quartile, and maximum. ‘‘o’’ in box-plot represents extremes and outliers. *, pr0.05;
Wilcoxon rank test, compared with CC. N.D—negligible detectable limit (o10 pg/ml).
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Fig. 4. PI3K and p38 pathway inﬂuence DC activation, but not virus replication during JEV infection. Wild-type JEV (WT), or vaccine JEV (Vac) infected or un-infected (CC)
im-MDDCs controls were cultured in the presence or absence of 5 mM PI3K inhibitor—LY294002 (LY), or p38 inhibitor—SB203580 (SB). (A) Cytokine levels in cell culture
supernatant (mean7SEM), (B) CD86 levels on im-MDDCs and (C) virus titers (TCID50/ml) in cell-culture supernatant. Data in panel (B) and (C) represents mean7SD of
three independent experiments.
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Fig. 5. Presence of IL2-activated CD56þ cells exerts immunomodulation and anti-
viral effect. Un-infected (CC), wild-type (WT), or vaccine (Vac) infected im-MDDCs
were cultured in medium alone or co-cultured with resting CD56þ (DCþCD56)
cells or IL2-activated CD56þ (DCþCD56act) cells at 1:1 ratio for 48 h. (A) CD86
levels on im-MDDCs (n¼7 donors), (B) cytokine and chemokine proﬁle (n¼7
donors, CXCL9¼4 donors), and (C) virus titer (TCID50/ml) on culture supernatant
(n¼6 donors). Data is represented as, (A) and (B) box-plots or (C) mean7SD. Box-
plots represent minimum, ﬁrst quartile, median, third quartile, and maximum. ‘‘o’’
in box-plot represents extremes and outliers. For (A) and (B) *, pr0.05; Wilcoxon
rank test; for (C) *, pr0.05; paired Student t-test, as compared with DC.
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replication of JEV strains. The phenomenon of refractive viral
replication in m-MDDCs has been reported during vaccinia(Engelmayer et al., 1999), DENV (Wu et al., 2000) and HIV
infections. The mechanism is more thoroughly studied in HIV
cis-infection, and it has been attributed to inhibition of viral
entry/fusion (Cavrois et al., 2006) or viral replication (Granelli-
Piperno et al., 1998; Bakri et al., 2001). The exact mechanism
behind refractive ﬂavivirus replication in m-MDDCs is not yet
clearly understood. During ﬂavivirus infection, receptor-mediated
endocytic pathway forms crucial mechanism for viral entry into
the host cell (Smit et al., 2011; Chu and Ng, 2004). Our pre-
liminary results also indicated that blockage of endocytic ability
of im-MDDCs renders them less susceptible to JEV growth (Fig.
S1). Therefore, JEV entry and replication in MDDCs might depend
on DC maturation state, with endocytic ability of the DC playing
an important role, rather than viral virulence.
Flaviviruses are known to induce DCs maturation (Dejnirattisai
et al., 2008; Ho et al., 2001; Li et al., 2011; Silva et al., 2007) and
PI3K and p38 pathways regulate virus speciﬁc immune response
(Mogensen and Paludan, 2001). As expected, JEV infection
resulted in im-MDDCs maturation and it was dependent on virus
replication, PI3K and p38 pathway. However, in contrast to
in vitro study on murine DCs (Aleyas et al., 2009; Cao et al.,
2011) our data suggested that the Indian wild-type (JE057434)
JEV strain did not inhibit DCs maturation, rather it had similar
ability as that of vaccine JEV to induce co-stimulatory markers in
human im-MDDCs. This variation might be due to the difference
in wild-type strain and/or the study model used in these studies.
During JEV infection, PI3K pathway is known to regulate early
apoptosis mechanism of the cell without hampering JEV replica-
tion (Lee et al., 2005). Likewise, our results also indicated that
PI3K and p38 regulate immune modulation of DCs without
affecting the JEV replication in im-MDDCs.
We also observed that, the wild-type JEV infection of im-
MDDCs resulted in an elevated amount of cytokines and chemo-
kines and induced a signiﬁcantly higher pro-inﬂammatory cyto-
kines (TNFa and IL8) than vaccine JEV. Some of the JEV-induced
cytokines/chemokines, such as CXCL10, CCL2, CCL5, and type-I
IFN, impart immunoprotection (Glass et al., 2005, 2006; Klein
et al., 2005), while TNFa and IL8 are known to be immunopatho-
genic (Ravi et al., 1997; Winter et al., 2004) to the host. Therefore,
the ability of wild-type JEV strain to induce DC activation, along
with elevated pro-inﬂammatory cytokine might potentiate a
probable immunopathogenic reaction.
In vivo CD56þ lymphocytes (NK/NKT) regulate DC maturation
as well as provide primary anti-viral defense at the periphery
(Biron and Brossay, 2001; Mu¨nz et al., 2005; Walzer et al., 2005).
Our results also showed that JEV infection resulted in CCL5, and
CCL2 release from im-MDDCs; these chemokine are known to
facilitate NK-cell chemotaxis (Loetscher et al., 1996; Maghazachi
et al., 1994) along with T cells and monocytes.
In accordance with previous reports (Gerosa et al., 2002, Piccioli
et al., 2002) our results indicated that presence of IL2-activated
CD56þ cells, but not resting CD56þ cells, resulted in DC maturation
and it was dependent on cell-to-cell contact and TNFa. It has also
been shown that PMA-activated T cells aid in DC maturations
during DENV infection (Dejnirattisai et al., 2008). Therefore, it is
possible that apart from innate lymphocytes other cells can also
contribute to DC maturation during ﬂaviviral infection.
Gerosa et al. (2005) have shown that co-culturing of
IL2-activated NK with stimulated DCs result in increased IFNa.
However, in our study, type-I IFN levels decreased, while TNFa
levels increased during co-culturing of JEV-infected DCs with
IL2-activated CD56þ cells. Type-I IFN and TNFa are known to
cross-regulate each other during certain disease conditions
(Palucka et al., 2005). Hence, we speculated that the decreased
type-I IFN might be due to increased TNFa levels. Nevertheless,
neutralizing TNFa, during JEV-infected im-MDDCs—CD56þ cells
Fig. 6. Immunomodulatory effect of IL2-activated CD56þ cells occurs through cell-to-cell contact and TNFa. Box-plot representing CD86 levels in un-infected (CC), wild-
type (WT), or vaccine (Vac) infected im-MDDCs, when co-cultured (A) in direct contact with IL2-activated CD56þ (DCþCD56act), or in transwell setup (DC/CD56act) (n¼4
donors); (B) direct co-culturing in the presence (DCþCD56actþantiTNF) or absence (DCþCD56act) of anti-TNFa (n¼5 donors). Box-plots represent minimum, ﬁrst
quartile, median, third quartile, and maximum. ‘‘o’’ in box-plot represents extremes and outliers. *, pr0.05; Wilcoxon rank test, as compared with corresponding
DCþCD56act.
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Therefore, the decrease in type-I IFN levels could probably be due
to direct lysis of IFN producing DCs by activated CD56þ cells.
One of the major hallmarks during DC–NK interaction is
production of IFNg by NK cells. Its induction is dependent on
IL12p70, IL15, IL18, E:T ratio and other factors (Ferlazzo et al.,
2004; Walzer et al., 2005). However, during our co-culture
experiments both IL12p70 and IFNg levels remained undetect-
able. High level IL12p70 induction from human DCs requires two
signals—CD40-40L interaction and IFNg (Snijders et al., 1998).
Role of external IFNg to induce IL12p70 from im-MDDCs has been
demonstrated during DENV infection (Libraty et al., 2001). Other
studies have also shown high levels of type-I IFN can inhibit
IL12p70, and consequently modulate IL12/IFNg axis (McRae et al.,
1998; Byrnes et al., 2007). Therefore, more studies would be
essential to understand the inability of JEV to induce IL12p70/
IFNg from DC or NK/NKT cells as it involves multiple regulatory
parameters.
Overall, the ability of CD56þ cells to reduce JE-viral load was
independent of TNFa, and primarily dependent on (i) CD56þ cell
activation status, (ii) direct cell-to-cell contact and (iii) E:T ratio.
On IL2-activation, there was an increased basal level degranula-
tion of CD56þ cells and more effective target-cell lysis. It isknown that at higher E:T (NK/DC) ratio there is potent killing of
autologous DCs (Piccioli et al., 2002), and mature NK-cells
mediate direct-cytolysis through Ca2þ dependent granule exocy-
tosis pathway or Fas ligand (Zamai et al., 1998). Therefore, CD56þ
cell mediated contact-dependent target lysis might play an
important role in controlling JE-virus load/spread in host tissues.
Interestingly, both JEV strains varied in their susceptibility
towards CD56þ mediated anti-viral effect, even though activated-
CD56þ mediated cell death remained similar in both JEV infected
im-MDDCs cultures. Therefore, this variation in anti-viral suscept-
ibility might be due to the intrinsic property of the virus. Such
variation in viral strain sensitivity to innate anti-viral state is
observed with other ﬂavivirus (Aguilar et al., 2005). Moreover, in
wild-type JEV infected cultures, increase in DC-CD86 levels during
IL2-activated CD56þ cells co-culture varied from donor to donor,
and was not as prominent as observed in un-infected and vaccine
JEV infected cultures. Therefore, it is alluring to speculate that
wild-type virus might undermine DC—IL2-activated CD56þ cell
interactions in few individuals.
Even though our in vitro results might not fully reﬂect the
in vivo scenario, it offers a preliminary insight into the interaction
of JEV with human DCs and NK/NKT cells. Based on our over-all
ﬁndings, we presume that the decreased cytokine levels and
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Fig. 7. IL2-activated CD56þ cells exhibited increased degranulation and DC killing ability. Two donor data-set of (A) CD107a levels in resting CD56þ (CD56, open bars) and
IL2-activated CD56þ (CD56act, ﬁlled bars) cells cultured in medium alone, or co-cultured with K562, K562þPMAþ ionomycin (positive control), un-infected/JEV-infected
im-MDDCs at 1:1 ratio. CD56þ cell mediated DC lysis was measured by CFSE-based cytotoxicity assay on CFSE-labeled DCs. (B) Total viable target-cell levels—CFSEþ DC
percentage, and (C) total dead target-cell levels—PIþ DC percentage. In panel (B) and (C) high-positive control—triton-X100 (0.1%) treated target-cells.
H. Sooryanarain et al. / Virology 432 (2012) 250–260 257increased susceptibility towards innate anti-viral effects of atte-
nuated vaccine JEV might facilitate efﬁcient virus clearance and
thus preventing virus spread into other tissues.In conclusion, interaction between JEV, im-MDDCs and
IL2-activated CD56þ cells is complex and would depend on both
viral and host factors. During JEV infection, DC/CD56þ cell
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compared with DC.
H. Sooryanarain et al. / Virology 432 (2012) 250–260258interaction might form one of the key factors in curtailing JEV at
the periphery while providing immunomodulation.Materials and methods
Cells lines and virus
Cell lines derived from, baby hamster kidney (BHK-21) and
human amnion (WISH) were maintained in Minimum essential
medium (MEM) supplemented with 10% fetal calf serum (FCS,
GIBCO, USA), 2 mM Glutamine, 100 U/ml Penicillin, and 100 mg/
ml Streptomycin. Wild-type (JE057434; WT), vaccine (SA14-14-2;
Vac) JEV strains and Encephalomyocarditis (EMC) virus were
propagated in BHK21 and WISH cells, respectively, to generate
working stocks. Aliquots of clariﬁed virus stocks were stored at
80 1C. Stock virus was titrated by plaque assay.
Antibodies and reagents
Human IFNa (reference standard) was obtained from the
National Institute for Biological Standards and Control (NIBSC,
London). PI3K, and p38 inhibitor (LY294002 and SB203580,
respectively) were procured from Sigma Aldrich, and stocks were
prepared and stored according to the manufacturer’s instructions.PE-conjugated anti-human CD80, CD86, HLA-DR, HLA-A/B/C,
CD83, ICAM1 and CD14, FITC-conjugated CD40, CD107a and
CD1a (BD Biosciences, USA) were used for ﬂow-cytometric stain-
ing of cell surface markers. Anti-human–TNFa neutralizing anti-
body and recombinant human cytokines, Granulocyte-Monocyte
colony stimulating factor (GM-CSF), IL4, and IL2 were procured
from R&D Systems, USA.Generation of immature and mature MDDCs
Buffy-coat packs from anonymous donations were obtained
from Sahyadri Hospital Blood Bank (Pune, India), as approved by
Institute (NIV, Pune) ethical committee. Peripheral blood mono-
nuclear cells (PBMCs) were isolated by Ficoll–Hypaque (Sigma,
USA) gradient separation. CD14þ cells were isolated from PBMCs
by positive selection using CD14 MicroBead mAbs (Miltenyi
Biotec, USA). To promote differentiation into im-MDDCs, 1106
puriﬁed CD14þ cells were cultured for 5–6 days in 5 ml of RPMI-
1640 (GIBCO, USA) supplemented with 10% FCS, 2 mM Glutamine,
100 U/ml Penicillin, 100 mg/ml Streptomycin and in the presence
of GM-CSF and IL4 (50 ng each). On day 3, half of the medium
was replenished with fresh medium and cytokines. The puriﬁed
im-MDDCs were stained with anti-CD14, CD80 and CD1a anti-
body on day 5; 90% cells were CD14CD1aþCD80þ . m-MDDCs
H. Sooryanarain et al. / Virology 432 (2012) 250–260 259were generated by incubating the puriﬁed im-MDDCs with LPS
(1 mg/ml) for 24 h.
Virus infection of MDDCs
1106 im-MDDCs or m-MDDCs were infected with either
wild-type or vaccine strain of JEV at a multiplicity of infection
(MOI) of one (unless otherwise mentioned) in complete medium
(RPMI-1640 þ10% FCS) for 1 h at 37 1C. All virus infections were
carried out in the absence of external neutralizing antibody or
autologous plasma. The cells were then washed thoroughly with
PBS to remove unadsorbed virus, and cultured in fresh complete
media supplemented with GM-CSF and IL4. A parallel un-infected
im-MDDCs control was also maintained. At 48 hpi, DC maturation
levels and cytokine and chemokine levels in culture supernatants
were estimated. Virus levels in culture supernatant were esti-
mated by tissue culture infective dose50 (TCID50) assay. Titers
were calculated as TCID50/ml using Spearman–Ka¨rber method.
DC–CD56þ cells co-culture
Peripheral CD56þ cells comprise both NK (CD56þCD3) and NKT
(CD56þCD3þ) population of innate lymphocyte. CD56þ cells were
isolated from PBMCs by positive selection using CD56-Microbead
mAbs (Miltenyi Biotec, USA). Isolated CD56þ cells were used directly
as resting cells or activated with IL2 (25 ng/ml) for 5 days to obtain
IL2-activated CD56þ . DC-CD56þ cross-talk were studied by co-
culturing un-infected/JEV-infected im-MDDCs with autologous rest-
ing or IL2-activated CD56þ cells at 1:1 ratio (unless mentioned).
Brieﬂy, the im-MDDCs were infected with JEV as mentioned above
and washed thoroughly to remove unadsorbed viruses. One-hour
post virus infection, the infected DCs were co-cultured with the
CD56þ cells. During the transwell (0.4 m pore-size) experiments, the
un-infected/JEV-infected im-MDDCs were maintained in lower cham-
ber while IL2-activated CD56þ cells were seeded in the upper
chamber. DC maturation levels and cytokine and chemokine levels
in culture supernatants were estimated at 48 hpi. Degranulation
assay (CD107a levels) to estimate CD56þ cells cytotoxic activity
was performed according to protocol described by Alter et al., 2004.
Brieﬂy, the cells were co-cultured as mentioned above along with
anti-CD107a-FITC (10 ml/ml), monensin (6 mg/ml), and brefeldin
(1 mg/ml), CD107a levels in CD56þ cells were estimated at 6 hpi.
K562 and K562þPMAþ ionomycin stimulus were used as known
positive controls.
Flow-cytometry analysis
After 48 h post JEV infection, im-MDDCs were harvested,
washed and resuspended in PBS with 0.5% BSA and 0.01% NaN3,
followed by incubation with PE-conjugated mAbs for 30 min at
4 1C. Cells were then washed and ﬁxed in 1% paraformaldehyde in
PBS. In each experiment, isotypic controls were used. Phagocytic
index was calculated based on percentage cells positive for FITC-
Dextran (FD40S, Sigma-USA) uptake. Cells were acquired using
the FACS-Calibur and data analyzed using CellQuest Pro software
(BD Biosciences, USA).
CFSE-based cytotoxicity assay
After washing with PBS the un-infected and JEV-infected
im-MDDCs (one-hour post virus adsorption) suspensions were
resuspended at 2106 cells/100 ml and labeled with 2 mM carboxy-
ﬂuorescein diacetate succinimidyl ester (CFSE; Invitrogen, USA) for
30 min at 37 1C. The reaction was stopped by the addition of ice-cold
PBS, followed by 5–10 min incubation. After two washes the CFSE-
labeled target were resuspended in assay medium and cellconcentration was adjusted to 2105 cells/ml, and was plated in
24-well microtiter plates. The cells were then cultured at 37 1C and
5% CO2 in the presence or absence of IL2-activated- or resting-
CD56þ cells, at various effector ratios. After 48 hpi, the cells were
harvested and to stain for dead cells, propidium iodide (0.5 mg/tube)
was added, and samples were mixed properly and directly analyzed
by ﬂow cytometry. Triton-X100 (0.1%, ﬁnal concentration) treated
cells were used as high-positive control.
Determination of type-I IFN and pro-inﬂammatory cytokine and
chemokine levels
Bioassay was employed to determine active type-I IFN levels.
Brieﬂy, two fold dilutions of JEV infected im-MDDCs culture
supernatants or hIFNa standards (1000 IU/ml, NIBSC) were added
onto pre-formed monolayer of WISH cells. After 18 h of incuba-
tion, the cells were infected with EMC virus. Type-I IFN titers were
expressed as IU/ml and were deﬁned as the reciprocal value of the
dilution of sample that showed a 50% reduction in virus induced
cytopathic effect. The lowest detectable type-I IFN concentration
was between 3–10 IU/ml. Cytokine (IL1b, IL6, IL8, IL10 and
IL12p70) and chemokine (CCL2, CCL5, CXCL10, and CXCL9) levels
on JEV-infected and un-infected im-MDDCs culture supernatants
was determined using CBA kit (BD Biosciences). TNFa levels were
estimated using DuoSet ELISA (R&D Systems).
Determination of anti-ﬂavivirus antibody
Donors’ sera were screened for the presence of N-Ab against
DENV, WNV, and JEV. In vitro neutralization test was performed
by incubating three-fold serially diluted donor’s sera samples
with 100 TCID50 of the test virus on BHK-21 cell-line. N-Ab titer of
serum samples was expressed as the reciprocal of the dilution at
which 50% of virus added was neutralized; a titer of 1:10 was
considered evidence of prior exposure.
Statistical analysis
Data is represented as bar-graphs representing mean7SD, or
boxplot. Statistical analysis was performed by paired-Student’s t-
test, or Wilcoxon signed-rank test for paired comparison, using
SPSS software (version 11). Differences at pr0.05 were consid-
ered statistically signiﬁcant.Acknowledgment
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